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ABSTRACT
VEGF-A and VEGF-B are proangiogenic and key regulating factors for blood vessel growth. This
study aims to compare VEGF-A and VEGF-B levels in the serum and vitreous of patients with
neovascular pathology versus non-neovascular pathology. Our findings showed vitreous VEGF-A
and VEGF-B levels increased in patients with neovascular disease, with higher levels of VEGF-A
compared to VEGF-B (p .05). In the diabetic retinopathy (DR) group, higher vitreous VEGF-A or
VEGF-B were found in proliferative diabetic retinopathy (PDR) than in non-PDR. The strong
correlation between VEGF-A and VEGF-B demonstrates a simultaneous pathological increase of
cytokines (p< .001), suggesting besides VEGF-A, VEGF-B is another contributor to ocular
pathologies involving angiogenesis. There was no correlation between vitreous and serum
VEGF-A or VEGF-B; however, a correlation between vitreous (VEGF-A or VEGF-B) and macular
volume (p< .05) in DR patients was found. Targeting VEGF-A and VEGF-B in macular and retinal
vascular diseases, involving neovascularization, may improve treatment outcomes.
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Angiogenesis is one of the mechanisms responsible for
neovascularization, in which new blood vessels are
contrived from the preexisting ones (Roy et al., 2006).
Neovascularization is not only an essential physiological
process like embryonic development but also induces
several pathological processes, for instance, tumour
growth, rheumatoid arthritis, psoriasis, and ocular dis-
eases such as age-related macular degeneration (AMD),
retinal vein occlusion (RVO) and diabetic retinopathy
(DR) (Ferrara et al., 2003). The resulting proliferation
often ends in visual impairment (Mesquita et al., 2018).
The vascular endothelial growth factor (VEGF) family
consists of seven members: VEGF-A, VEGF-B, VEGF-C,
VEGF-D, VEGF-E, VEGF-F and placental growth factor
(PlGF) (Li et al., 2009). Alternative splicing results in
several VEGF variants or isoforms (Penn et al., 2008).
VEGF-A is implicated in the angiogenesis of patho-
logical eye conditions and, thus, is a highly significant
therapeutic target (Witmer, 2003). Carmeliet et al. (1996)
and Ferrara et al (1996) showed the essential role of
VEGF-A in embryonic vasculogenesis and angiogenesis.
VEGF-A induces an angiogenic response, essential in
inflammation due to its capacity to increase vascular
permeability and induce vascular leakage (Amadio et al.,
2016). VEGF-A exists in four different isoforms created
due to alternative exon splicing: VEGF121, VEGF165,
VEGF189, and VEGF206; VEGF165 is the most predomin-
ant isoform (Houck et al., 1991). VEGF-A binds to two
receptor tyrosine kinases, that is, VEGF receptor 1
(VEGFR-1) and VEGF receptor 2 (VEGFR-2), and
also binds to neuropilin-1 (NRP-1) and neuropilin-2
(NRP-2). VEGFR-1 and VEGFR-2 regulate and signal
physiological and pathological angiogenesis (Shibuya,
2006). Binding to VEGFR-1 promotes tumour growth,
metastasis, and inflammation (Shibuya, 2006).
VEGF-B, a closely related molecule to VEGF-A, is
one of the least studied members and the most con-
troversial protein of the VEGF family (Li et al., 2009).
The biological function of VEGF-B is enigmatic. Li
and coworkers (2012) referred to VEGF-B as a multi-
functional safeguarding molecule having a functional
ambiguity role. VEGF-B has low angiogenic activity;
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however, it is a potent anti-apoptotic, rescuing vessels
from death. It plays a specific role in angiogenesis
during the repair process after brain injury and myo-
cardium revascularization after myocardial infarction
(Li et al., 2008; Nag et al., 2002). VEGF-B also plays
an important role in the lipid metabolism, and its
impairment causes obesity due to absorption and
accumulation of fatty acids in the tissues. It was
shown that lipid accumulation in the pathological
tissue impairs insulin signalling, leading to insulin
resistance and metabolic dysfunction and resulting in
type-2 diabetes mellitus. Moreover, lipids in circula-
tion are transported through vascular endothelium up
to the tissue cells to help them perform their func-
tions. VEGF-B regulates this process by controlling
the expression of the endothelial fatty acids trans-
porter protein, more specifically the regulation of
endothelial cells long chain fatty acids uptake through
VEGFR-1 and NRP-1 (Hagberg et al., 2010, 2013;
Muhl et al., 2016). In vivo, VEGF-B causes choroidal
and retinal neovascularization (Zhang et al., 2009).
The ‘angiogenic’ activity of VEGF-B during ocular
neovascularization is due to its vascular survival effect
mediated by NPR-1 and VEGFR-1, which safeguards
the neovessels from apoptosis (Zhang et al., 2009).
Therefore, direct VEGF-B inhibition may be a poten-
tial therapy for the treatment of ocular neovascular
diseases (Zhang et al., 2009). Alternative splicing of
exon 6 resulted in two isoforms of VEGF-B:
VEGF-B167 and VEGF-B186. VEGF-B binds with high
affinity to VEGFR-1 but not to VEGFR-2 or VEGF
receptor 3 (VEGFR-3), competing with VEGF-A for
VEGFR-1 binding (Olofsson et al., 1998). This select-
ive binding is due to electrostatic surface potentials
(Iyer et al., 2010).
Moreover, VEGF-A may also generate heterodimers
with VEGF-B, affecting the formation of VEGF-A
homodımers and bioavailability of VEGF-A to bind to
its receptors and exert its activity (Olofsson et al., 1996).
Evidences show that patients with retinal diseases, such
as DR, AMD, and RVO, have increased levels of vitreous
VEGF-A (Aiello et al., 1994). Our research group has
shown increased vitreous levels of VEGF-B in DR and its
association with disease severity (Mesquita et al., 2017).
With the growing interest in the use of anti-
angiogenics in the treatment of different diseases
related to anomalous angiogenesis, inflammation and
vessel hyperpermeability, more consideration must be
paid to understand the accurate roles of the molecules
of the VEGF family (Li et al., 2009).
In the present study, we investigated two cytokines
levels (VEGF-A and VEGF-B) in vitreous and serum
associated with neovascular eye pathologies: DR,
AMD and RVO. Quantitative results and clinical
characteristics of VEGF-A and B were compared
between two groups of patients (neovascular and non-
neovascular). For further exploration, the serum and
vitreous concentration levels of VEGF-A or VEGF-B
(in the neovascular group) were correlated with stage
of DR to confirm if there was a growth of cytokines
levels with disease progression, previous treatments,
functional parameters, such as visual acuity and
structural parameters, such as macular volume and
central retinal thickness, assessed by optical coherence
tomography (OCT).
A better knowledge of these cytokines and their
correlation can lead us to better-targeted precise and
specific therapies. This may also lead to disease pre-
vention through the detection of ocular neovasculari-
zation before the appearance of clinical symptoms,
subsequently leading to the prevention of blindness.
Materials and methods
Participants
This retrospective study involved 20 patients divided
into two groups: (1) A neovascular group (n¼ 17) com-
prising RVO (n¼ 2), AMD (n¼ 2) and DR (n¼ 13)
patients and (2) A non-neovascular group (or control
group), which included patients with vitreomacular
traction (VMT) syndrome (n¼ 3) of idiopathic aeti-
ology but without any other ocular disorder (including
neovascular disease).
The neovascular ocular disease was defined for this
study as a retinal disease associated with abnormal
blood vessel growth, which may lead to blindness; how-
ever, the location of neovascularization may differ.
The DR group was classified into patients with pro-
liferative diabetic retinopathy (PDR) (n¼ 8) and non-
proliferative diabetic retinopathy (NPDR) (n¼ 5).
For the DR group, the diabetes mellitus duration
was defined as the duration from the first diagnosis of
diabetes mellitus to the time of vitrectomy and sample
collection. None of the patient samples selected for the
study had undergone either pharmacological (intravi-
treal injections) or laser treatments within the 3months
of vitrectomy. Moreover, diabetic therapy remained
unchanged for at least 3months before vitrectomy.
A naïve patient was defined as a patient who has
never been treated before for ocular conditions with
any drug or non-drug therapy, including laser photo-
coagulation, bevacizumab, ranibizumab, aflibercept or
triamcinolone.
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Collection of samples and storage
Whole blood samples were collected from patients
before the surgery. After allowing the blood to clot at
room temperature for 30 minutes, the clot was removed
by centrifugation at 3000 rpm for 10 minutes. After
serum withdrawal, it was immediately frozen at 80 C.
Each patient underwent Pars Plana Vitrectomy (PPV)
for treatment of the current disease. The undiluted
vitreous samples were collected at the beginning of
the PPV in sterilized tubes, placed immediately on ice
and frozen at 80 C until it was required for analysis.
The criteria for the samples were as follows:
1. Patients with a confirmed diagnosis of neovascu-
lar ocular disease (for the neovascular group)
were included.
2. For the control group, non-diabetic patients with
no PDR and no signs of neovascularization, ret-
inal vascular occlusion or other ocular disorder,
except VMT syndrome, were included.
3. For the diabetic population, all patients with dia-
betic treatment either stable or unchanged for at
least 3 months before the vitrectomy procedure
were included.
4. Patients with sample volume that would allow the
confirmation of the results through repeated
enzyme-linked immunosorbent assay (ELISA) for
the determination of VEGF-A and VEGF-B levels
simultaneously in both vitreous and serum.
5. Patient samples were excluded from the analysis
if the patients performed any intravitreal treat-
ment (with anti-VEGFs and/or corticosteroids) or
laser therapy less than 3 months of vitrectomy.
Moreover, due to the limitation of sample size,
restrictions due to controlled inclusion/exclusion crite-
ria and the difficulty in the collection of proper large
vitreous sample sizes, the conclusions in an overall
population should be done drawn with caution.
Collection of retrospective data from patients
Clinical history of the patients was collected to con-
firm the diagnosis, concurrent diseases as well as base-
line and clinical characteristics. Despite the exclusion
of patients from the study, information on their previ-
ous concomitant eye treatments was collected.
Measurement of vitreous and serum VEGF-a and
VEGF-B levels
ELISA was performed to measure the vitreous and
serum levels of VEGF-B (VEGF-B ELISA Kit; Ref,
E-EL-H2164; Elabscience; Wuhan, Hubei, China) and
VEGF-A (VEGF-A ELISA Kit; Ref, E-EL-H0111;
Elabscience; Wuhan, Hubei, China). Both analyses were
conducted according to manufacturer instructions.
Measurement of structural parameters
OCT examinations were performed before PPV using
the Heidelberg equipment (Heidelberg Engineering,
Heidelberg, Germany). Thickness mapping of retinal
layers was used to measure the central retinal thick-
ness (CRT) and macular volume (MV) associated
with the retinal pathologies.
Measurement of functional parameters
Best corrected visual acuity (BCVA) was measured with
early treatment diabetic retinopathy study (ETDRS)
charts (Precision Vision, La Salle, IL) at 4 m.
Statistical analysis
Statistical analysis was performed using IBM SPSS
version 24.0 (IBM Corp., Armonk, NY) for Windows.
A level of significance (a) 0.05 was set to reject the
null hypothesis. Pearson test was used to correlate
quantitative variables with a normal distribution while
Spearman’s correlation coefficient test was used to
correlate quantitative variables without normal distri-
bution. The Mann–Whitney was used to compare two
groups on quantitative dependent variables, without
normal distribution.
Ethical statement
The study was approved by the Institution Review
Board, named Ethics Committee for Health of Centro
Hospitalar de Leiria (CHL-15481) and Portuguese
National Data Protection Commission. All patients
included in this study, adhered to the tenets of the
Declaration of Helsinki, gave their informed consent
after appropriate explanation.
Results
Study population: baseline characteristics
In this retrospective study, samples from 20 patients
(5 women and 15 men) with a mean age of 70.3 years
were selected to be analysed based on specific inclu-
sion and exclusion criteria.
Two of the patients with RVO submitted to PPV
surgery had active neovascularization. Out of the two
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AMD patients, one had active neovascularization and
the other had reminiscent neovascularization at the
time of surgery (confirmed by fluorescein angiog-
raphy). The patient with reminiscent neovascularization
was previously treated (more than 3months before
surgery) with 8 bevacizumab intravitreal injections
(before approval of the license drug ranibizumab), 4
ranibizumab injections (after approval of ranibizumab
by health authorities) and 5 aflibercept injections.
From the 13 diabetic patients analysed, eight had
PDR and five had NPDR. The majority had DM type 2,
with the exception of 1 patient who had DM type 1.
This patient (with DM type 1) had PDR and was under
insulin treatment. The other 12 patients with DM type
2 were under insulin therapy (n¼ 2), oral therapy
(n¼ 8) or both insulin and oral therapy (n¼ 2).
Concerning the previous treatments undergone by
the patients (3months before the PPV), in the neovas-
cular group, eight patients were naïve to treatment: 1
RVO, 1 AMD and 6DR (2 patients had PDR and 4 had
NPDR), and nine patients were non-naïve to the treat-
ment. The non-naïve patients included one RVO, one
AMD and seven DR patients (6 patients with PDR and
1 with NPDR). The control group did not have any
ocular neovascular pathology besides VMT syndrome.
Characterization of the baseline demographic and
clinical characteristics is summarized in Table 1.
After characterization, this pool of patients was
re-grouped into the neovascular group and non-
neovascular group as defined previously.
Comparison of vitreous and serum VEGF-a and
VEGF-B levels between patients with neovascular
and non-neovascular diseases
A statistically significant difference was observed
between vitreous VEGF–A in the neovascular group
[(343.30 ± 543.82 pg/mL), (mean ± standard deviation)]
and vitreous VEGF-A in the non-neovascular group
[(7.04 ± 1.35 pg/mL), (Z¼1.958, p¼ .050)]. Likewise,
the mean difference of vitreous VEGF–B concentra-
tion was significantly higher in the neovascular
group (208.83 ± 353.58 pg/mL) than the control
group of non-neovascular disease [(1.94 ± 0.61 pg/mL)
(Z¼2.170, p¼ .030)] (Figure 1).
Regarding the analysis of the serum, there were
differences between the two groups (neovascular and
non-neovascular), although these differences were not
statistically significant (Figure 1).
Comparison of VEGF-a and VEGF-B levels in
vitreous and serum of studied pathologies
The comparison between vitreous VEGF-A and vitre-
ous VEGF-B levels showed an increase in both DR
and RVO patients. AMD patients revealed lower vitre-
ous levels for both cytokines (VEGF-A and VEGF-B),
suggesting that this result is due to one patient who
had reminiscent neovascularization (Figure 2).
Serum levels of VEGF-A and VEGF-B did not
reveal any significant difference between neovascular
pathologies and control group.
Table 1. Patient baseline clinical and demographic characteristics.
Total (n¼ 20) RVO (n¼ 2) AMD (n¼ 2) DR (n¼ 13) Control group (n¼ 3)
Demography
Age (yrs) (Mean, SD) 70.3 ± 10.7 78.0 ± 5.6 77.0 ± 7.0 68 ± 11.9 71.0 ± 6.2
Other variables
BCVA (ETDRS letters) at baseline (Mean, SD) – 65.0 ± 1.5 48.0 ± 3.5 62.1 ± 19.2 57.5 ± 3.5
CRT at baseline (Mean, SD) – 328.5 ± 30.4 480.5 ± 140.7 413.8 ± 65.7 –
MV at baseline (Mean, SD) – 8.07 ± 0.06 11.79 ± 3.08 9.59 ± 1.67 –
Diabetes mellitus type (n; %) in DR patients group
DM 1 (n, %) – – – 1, 8.3% –
DM 2 (n, %) – – – 12, 91.7% –
Diabetes treatment (n; %) stable for at least 3 months before vitrectomy procedure
Insulin therapy – – – 3 27.3 –
Oral therapy – – – 8 54.5 –
Insulin and oral therapy – – – 2 18.2 –
Other DR characteristics
Duration of DR (yrs) (Mean, SD) – – – 1.6 ± 1.5 –
PDR (n; %) – – – 8, 38.5 –
NPDR (n; %) – – – 5, 61.5 –
Previous treatments for ocular condition (performed more than 3 months before vitrectomy)
Laser photocoagulation (n) – 1 0 7 –
Bevacizumab (n) – 0 1 0 –
Ranibizumab (n) – 0 1 3 –
Aflibercept (n) – 0 1 0 –
Triamcinolone (n) – 0 0 2 –
VEGF-A: vascular endothelial growth factor A; VEGF-B: vascular endothelial growth factor B; BCVA: best corrected visual acuity; CRT:
central retinal thickness; MV: macular volume; RVO: retinal vein occlusion; AMD: age macular degeneration; DR: diabetic retinopathy;
PDR: proliferative diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy; DM1: diabetes mellitus type 1; DM2: diabetes
mellitus type 2; control group: patients with vitreomacular traction syndrome of idiopathic aetiology and without other ocular disor-
ders; yrs: years; SD: standard deviation.
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Comparison of vitreous and serum levels of VEGF-a
and VEGF-B between PDR and NPDR patients
Analysis of the DR patients revealed statistical differ-
ences in VEGF-A and VEGF-B levels:
(a) Vitreous VEGF-A levels were higher in PDR
(576.88 ± 681.15 pg/mL) than in NDPR (39.11 ±
71.13 pg/mL) (Z¼2.342, p¼ .019);
(b) Vitreous VEGF-B levels were also higher in PDR
(357.55 ± 453.22 pg/mL) than in NDPR (17.75 ±
34.92 pg/mL) (Z¼2.342, p¼ .019);
(c) Serum VEGF-A levels were increased in NPDR
(95.08 ± 47.37 pg/mL) compared to PDR (36.02 ±
28.05 pg/mL) (Z¼2.196, p¼ .028);
(d) Serum VEGF-B levels were higher in NPDR
(46.38±22.35pg/mL) than in PDR (17.29±14.74pg/mL)
(Z¼2.049, p¼ .040) (Figure 3).
Comparison of vitreous VEGF-a and VEGF-B levels
between naïve and non-naïve patients with
neovascular pathology
For this analysis, as defined previously, a non-naïve
was a patient who never underwent any drug or non-
drug therapy to treat his/her ocular disease, including
laser photocoagulation, bevacizumab, ranibizumab,
aflibercept or triamcinolone.
Although the analysed patients had performed
intravitreal treatments and/or laser therapy 3months
before vitrectomy, a comparison of the mean values
between naïve (n¼ 8) and non-naïve (n¼ 9) patients
in the neovascular group (n¼ 17) demonstrated a
statistically significant difference (p< .05) between vit-
reous VEGF-A and VEGF-B. Higher levels of vitreous
VEGF-A and VEGF-B in the group of non-naïve
patients was observed (Table 2).
Analysis of vitreous VEGF-a and VEGF-B levels in
the group of patients with neovascular disease
per treatment group
For this analysis, the non-naïve neovascular patients
(n¼ 9) were divided into five groups, describing the
Figure 1. Mean serum and vitreous VEGF-A and VEGF-B concen-
trations between the neovascular (n¼ 17) and non-neovascular
(n¼ 3) study arm, analysed with Mann–Whitney test (p< .05). Figure 2. Mean vitreous and serum levels of VEGF-A and
VEGF-B among different studied pathologies and control group
of patients, analysed with Mann–Whitney test (p> .05).
VEGF-A: vascular endothelial growth factor; VEGF-B: vascular
endothelial growth factor B; RVO: retinal vein occlusion (n¼ 2);
DR –diabetic retinopathy (n¼ 13); AMD: age macular degener-
ation (n¼ 2). The control group included patients with VMT
syndrome with no other ocular disorders (n¼ 3).
Figure 3. Comparison of the mean vitreous and serum levels of
VEGF-A and VEGF-B between NPDR (n¼ 5) and PDR (n¼ 8), ana-
lysed with Mann–Whitney test (p< .05). PDR: proliferative dia-
betic retinopathy, NPDR – non-proliferative diabetic retinopathy.
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treatments performed since they were diagnosed until
vitrectomy (note that the selected samples for the
neovascular group did not undergo any treatment
3months before the surgery):
Group A: patients who were administered only laser;
Group B: patients who were administered bevacizu-
mab, ranibizumab and aflibercept;
Group C: patients who were administered ranibizu-
mab and laser;
Group D: patients who were administered laser
and triamcinolone;
Group E: patients who were administered laser,
triamcinolone and ranibizumab.
Overall, the results revealed high vitreous levels of
both growth factors as seen in Figure. 4.
Correlation between vitreous VEGF-a and vitreous
VEGF-B, serum VEGF-a and serum VEGF-B in the
neovascular group of patients
There was a statistically significant, positive and
strong correlation between vitreous VEGF-A and vit-
reous VEGF-B in patients with neovascular pathology
(n¼ 17), that is, rsp¼ 0.983, p< .001. Likewise, there
was a positive and strong correlation between serum
VEGF-A and serum VEGF-B (r¼ 0.970, p< .001) in
the neovascular group (Figure 5).
Similarly, the correlation coefficient between
VEGF-A and VEGF-B in vitreous and serum for DR
patients (n¼ 13) was statistically significant, positive
and strong; rsp¼ 0.984, p< .001 and rsp¼ 0.973,
p< .001, respectively (Figure 6).
Correlation between vitreous and serum VEGF-a
and between vitreous with serum VEGF-B in the
neovascular group of patients
The correlation coefficient between vitreous VEGF-A
and serum VEGF-A for the neovascular group was
not statistically significant (n¼ 17; rsp¼0.051;
p¼ .844). Also, there was no correlation between
vitreous VEGF-A and serum VEGF-A in the DR
patients group (n¼ 13; rsp¼0.209; p¼ .494).
Similarly, the correlation coefficient between vitreous
VEGF-B and serum VEGF-B levels was not statistically
significant for neovascular patients’ population (n¼ 17;
rsp¼ 0.027; p¼ .918). Relatively to DR patients, there
was no correlation between vitreous VEGF-B and
serum VEGF-B (n¼ 13; rsp¼0.110; p¼ .721).
Correlations of vitreous VEGF-a or vitreous VEGF-B
with structural and functional parameters in
DR patients
In the DR patients group, a statistically significant,
positive and moderate correlation was observed
between vitreous VEGF-A and MV (rsp¼ 0.560,
p¼ .046) and between vitreous VEGF-B and MV
(rsp¼ 0.588, p¼ .035). No statistically significant
correlation was found either for the visual acuity or
CRT (Table 3).
Discussion
VEGF-A is not only the prototype angiogenic factor
but also a mediator of angiogenesis and vascular per-
meability in inflammatory disorders (Amadio et al.,
2016). VEGF-B, unlike VEGF-A, is insignificant in
angiogenesis or vascular permeability (Li et al., 2012).
Its role is to be a survival factor in pathological
Table 2. Comparison of the mean concentration levels of vit-
reous VEGF-A and vitreous VEGF-B in the neovascular group
between naïve and non-naïve patients (p< .05).
Patients in the neovascular group (n¼ 17)
Non-
naïve (n¼ 9) Naïve (n¼ 8)
Mean SD Mean SD Z p
Vitreous VEGF-B 321.48 441.11 82.09 169.42 1.925 .054
Vitreous VEGF-A 516.26 665.50 148.71 296.79 2.021 .043
VEGF-A: vascular endothelial growth factor A, VEGF-B: vascular endothelial
growth factor B, SD: Standard deviation.
Figure 4. Mean vitreous concentration levels of VEGF-A and
VEGF-B among the 5 treatment groups in the neovascular
patients group (non-naïve patients, n¼ 9), using descriptive
analysis. VEGF-A: vascular endothelial growth factor; VEGF-B:
vascular endothelial growth factor B; Group A: Patients that
only performed laser treatment; Group B: Patients that per-
formed either or, ranibizumab, bevacizumab, aflibercept; Group C:
Patients treated with ranibizumab plus laser; Group D: Patients
treated with triamcinolone and laser; Group E: patients treated
with ranibizumab plus triamcinolone plus laser; SD: stand-
ard deviation.
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processes in several body systems such as the eye,
brain or heart (Zhang et al., 2009).
Our results demonstrated that vitreous VEGF-A and
VEGF-B are increased in patients with neovascular dis-
eases as compared to the control group of patients
with non-neovascular diseases. The pathologies which
had higher concentrations of vitreous VEGF-A and
VEGF-B were RVO and DR, supporting the assump-
tions that these cytokines are important contributors in
the pathogenesis of neovascular eye diseases (Li et al.,
2009). Enhanced concentrations of both factors were
also expected in AMD patients, but such results were
not observed due to the fact that one AMD patient
was in a reminiscent phase of the disease, despite being
treated more than 3months before the PPV. Moreover,
increased levels of VEGF-A than VEGF-B demon-
strated that the development of new drugs is in the
right direction by inhibiting the growth factor A.
A combination action of drugs causing VEGF-A
inhibition while targeting VEGF-B (apoptotic propri-
eties) should be beneficial (Li et al., 2012).
Concerning the analysis of DR patients, an investi-
gative analysis demonstrated statistically significant
and high values of vitreous VEGF-A and VEGF-B in
PDR patients, suggesting the increase in VEGF-A and
VEGF-B levels with the progression of the disease
and, thus, confirming the benefit of inhibiting those
two cytokines in the treatment of DR. Research
reports from Funatsu et al. (2002), Gao et al. (2016)
and Watanabe et al. (2005) also demonstrated
increased levels of vitreous VEGF-A in PDR patients
as compared to their control group. In addition, evi-
dences are provided that vitreous VEGF-B levels are
increased in diabetics and depend on disease severity
from NPDR to PDR (Mesquita et al., 2017). In con-
trast, the results obtained with serum samples in the
DR patients showed higher VEGF-A and VEGF-B lev-
els in NPDR. Higher serum VEGF-A levels have been
determined by some investigators in NPDR patients
as compared to PDR (Burgos et al., 1997; Hernandez
et al., 2001; Krizova et al., 2015; Lee et al., 2005;
Praidou et al., 2009; Simo et al., 2002), whereas others
described no serum level differences among distinctive
groups of diabetics (Aiello et al., 1994; Burgos et al.,
1997; Hernandez et al., 2001, 2002; Krizova et al.,
2015; Praidou et al., 2009; Simo et al., 2002).
Figure 5. Correlation between (a) vitreous VEGF-A versus vitreous VEGF-B and (b) serum VEGF-A versus serum VEGF-B (in patients
with neovascular pathology, n¼ 17), analysed by Spearman’s correlation (in vitreous samples) and by Pearson correlation coeffi-
cient (in serum samples) (p< .001).
Figure 6. Correlation between: (a) vitreous VEGF-A versus vit-
reous VEGF-B and (b) serum VEGF-A versus serum VEGF-B, in
DR patients, (n¼ 13), analysed by Spearman's correlation coef-
ficient (p< .001).
Table 3. Correlations between structural (CRT and MV), func-
tional parameters (VA) and concentration levels of vitreous
VEGF A and B in a group of DR patients (n¼ 13), analyzed by
Spearman’s correlation coefficient (p< .05).
CRT MV BCVA
Vitreous VEGF-B levels (pg/mL) 0.008 0.588 0.103
Vitreous VEGF-A levels (pg/mL) 0.041 0.560 0.118
p .05.
VEGF-A: vascular endothelial growth factor A; VEGF-B: vascular endothelial
growth factor; CRT: central retinal thickness; MV: macular volume; BCVA:
best corrected visual acuity.
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A hypothesis mentions that the high VEGF-A and
VEGF-B serum concentration levels in the NPDR are
due to undiagnosed concurrent systemic diseases,
such as cancer and rheumatoid arthritis, that may
alter serum VEGF-A values, especially in our analyzed
aged population (Ferrara et al., 2003; Mesquita et al.,
2018). Another hypothesis suggests that the stage of
DR and diabetic therapy may alter VEGF results as
demonstrated by Baharivand and coworkers (2012),
which showed that serum VEGF-A levels are lower in
diabetics on oral therapy, well-controlled diabetes
cases, and in early stages of DR. One last hypothesis
to explain our results is through the fact that the pro-
duction of VEGF-A or VEGF-B by the retina may not
be related with their systemic levels. In this case, while
Lee, Chae and Kim (2005) attributed the progression
of DR to the circulating systemic VEGF-A, Burgos
et al. (1997) and Funatsu et al. (2002) suggested that
not the serum diffusion, but the intraocular synthesis
of VEGF was the principal contributing factor for the
high VEGF-A levels observed in the vitreous humor
of PDR patients. To confirm this hypothesis, we
showed in our study no correlation between serum
and vitreous levels of either VEGF-A and VEGF-B,
proposing a dissociation between the eye and other
organs and an intraocular synthesis of vitreous VEGF-
A and VEGF-B. Other researchers measured the levels
of VEGF-A in vitreous and serum of patients and
tried to find a correlation between serum and vitreous
(Abdel et al., 2008; Aiello et al., 1994; Ambati et al.,
1997; Baharivand et al., 2012; Burgos et al., 1997;
Celik et al., 2005; Deng et al., 1999; Funatsu et al.,
2002; Gao et al., 2016; Hernandez et al., 2001, 2002;
Hogeboom et al., 2002; Krizova et al., 2015; Lee et al.,
2005; Malik et al., 2005; Ozturk et al., 2009; Praidou
et al., 2009; Simo et al., 2002; Watanabe et al., 2005;
Zhou & Zhang, 1997). However, most of the research-
ers did not find any correlation with the exception of
Baharivand and colleagues (2012) who found a posi-
tive correlation between serum and vitreous VEGF-A.
The comparison of vitreous VEGF-A and vitreous
VEGF-B (in non-naïve patients) with the five treatment
groups in the neovascular population suggested the
existence of disease recurrence. Anti-VEGFs are the
gold standard treatment for neovascular and potentially
blinding diseases, although there are limitations to the
use of such therapies. One limitation is the unknown
duration of anti-neovascular effects. Anti-angiogenics
reduce progression of neovascularization after the treat-
ment, but the duration of the effect is for a limited
time. Some patients require several intravitreal injec-
tions to achieve successful treatment or stabilized
condition while others respond insufficiently even with
several antiangiogenic treatments (Singer et al., 2016).
Another limitation is the detectable antiangiogenic
drug levels in the systemic circulation that may cause
an increase in thromboembolic and cardiovascular
events. Although the death rates do not seem to be
increased due to the use of antiangiogenic drugs, their
long-term consequences are still unknown (Singer
et al., 2016). Lastly, VEGF-A and VEGF-B play an
important role in neuroprotection, including the retinal
neurons, and cell survival. Therefore, VEGF-A and
VEGF-B blockage may also cause significant adverse
events if there is a significant systemic distribution of
the drugs (Singer et al., 2016).
An interesting finding was the significant correl-
ation between VEGF-A and VEGF-B either in serum
or vitreous, demonstrating that they can increase sim-
ultaneously. This may support the statement that
VEGF-B, besides VEGF-A, is another important con-
tributor to the pathogenesis of angiogenic diseases.
A statistically significant and positive correlation
was found between vitreous VEGF-A and MV or
between vitreous VEGF-B and MV in the diabetic
population, demonstrating their effects in the estab-
lishment of oedema.
Overall, the results suggest an overexpression of
vitreous VEGF-A and VEGF-B, with higher levels of
VEGF-A and a simultaneous increase of those cyto-
kines in neovascular eye pathologies. It was also con-
firmed that vitreous VEGF-A and VEGF-B increase
with stages of DR, being more enhanced in PDR
patients. Both are correlated with the increase in MV,
demonstrating the importance of those cytokines in
the establishment of macular oedema.
There are several pharmaceutical agents and non-
drug procedures available to battle these multifactorial
neovascular diseases. Despite lasers and anti-angiogenics
being the leading treatments for neovascular diseases,
about 50% of patients have an insufficient response
to angiogenic therapy. Some would benefit from an
early therapy switch as shown in the EARLY studies
(Gonzalez et al., 2016). The combination therapy may
be the rational approach to fight neovascular diseases
by targeting VEGF factors while combating multiple
and complex factors in the inflammatory and angio-
genic cascade.
Only with a profound knowledge of pathophysi-
ology, vascular, inflammatory and biochemical mecha-
nisms of the targeted molecules, it will be possible to
develop a new treatment approach. Thus, targeting
VEGF-A or/and VEGF-B as an additional treatment
options for neovascular ocular diseases might provide
8 J. MESQUITA ET AL.
better outcomes, sustained duration of action, and
increased efficiency.
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